FDA Approves GSK's Jemperli for First-Line MSI-High, dMMR Rectal Cancer

The US FDA has granted accelerated approval to GSK's immunotherapy Jemperli (dostarlimab) as a first-line treatment for stage II/III locally advanced rectal cancer that is MSI-high or mismatch repair deficient.

This Wire brief sits within Fusion42's coverage of Drug Discovery, and 7 sources have reported it.